BioNTech SE (BNTX) — Analyst outlook / Analyst consensus target is. Based on 24 analyst ratings, the consensus is bullish — 20 Buy, 4 Hold.
The consensus price target is $137.38 (low: $113.00, high: $155.00), representing an upside of 39.6% from the current price $98.41.
Analysts estimate Earnings Per Share (EPS) of $-3.31 and revenue of $2.66B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.77 vs est $-3.31 (beat +16.2%). 2025: actual $-4.51 vs est $-3.51 (missed -28.4%). Analyst accuracy: 79%.
BNTX Stock — 12-Month Price Forecast
$137.38
▲ +39.60% Upside
Average Price Target
Based on 24 Wall Street analysts offering 12-month price targets for BioNTech SE, the average price target is $137.38, with a high forecast of $155.00, and a low forecast of $113.00.
The average price target represents a +39.60% change from the last price of $98.41.
Highest Price Target
$155.00
Average Price Target
$137.38
Lowest Price Target
$113.00
BNTX Analyst Ratings
Buy
Based on 24 analysts giving stock ratings to BioNTech SE in the past 3 months
EPS Estimates — BNTX
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$2.77
vs Est –$3.31
▲ 19.3% off
2025
Actual –$4.51
vs Est –$3.51
▼ 22.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BNTX
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.751B
vs Est $2.655B
▲ 3.5% off
2025
Actual $2.757B
vs Est $2.718B
▲ 1.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
